Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT05701423
- Locations
- 🇩🇪
Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT05658484
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Xiangya Hospital Central South University, Changsha, China
🇨🇳West China Hospital of Sichuan University, Chengdu City, China
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 908
- Registration Number
- NCT05658497
- Locations
- 🇺🇸
IQVIA US Office, Durham, North Carolina, United States
🇩🇪Katholisches Klinikum Bochum, Bochum, Nordrhein Westfalen, Germany
🇮🇪St Vincent's University Hospital, Dublin, Ireland
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 19
- Registration Number
- NCT05655507
- Locations
- 🇺🇸
Sage Investigational Site, Cincinnati, Ohio, United States
Adult Spinal Muscular Atrophy (SMA) China Registry
- Conditions
- Muscular Atrophy, Spinal
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT05618379
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Learn About the Safety of Salanersen (BIIB115) Injections and How Salanersen is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
- Conditions
- Healthy VolunteerMuscular Atrophy, Spinal
- Interventions
- Drug: Salanersen-Matching Placebo
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 62
- Registration Number
- NCT05575011
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇨🇦Children's Hospital of Eastern Ontario, Ontario, Canada
🇫🇷Hôpital Armand Trousseau, Paris, France
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)
- Conditions
- Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 474
- Registration Number
- NCT05531565
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸UAB Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1
- Registration Number
- NCT05532163
- Locations
- 🇩🇪
Neurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg, Germany
🇩🇪Neurologische Studiengesellschaft Bonn GbR, Bonn, Germany
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122-Matching Placebo
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 7
- Registration Number
- NCT05418673
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado, United States